viewSensyne Health PLC

Sensyne Health 'achieves primary IPO objective' with a database with over 5m records

Sensyne Health PLC's (LON:SENS) CEO Lord Paul Drayson talks to Proactive London's Katie Pilbeam about 'achieving their primary IPO objective' with a database over 5m records.

This comes after its strategic research agreement with Somerset NHS Foundation Trust which pulls in 1.1mln unique records from a population of 600,000. In total, the company now has information for 5.6mln patients.

Drayson says the most important thing is the insights which improve patients' care, 'being able to identify the risk factors which enable doctors to better predict stroke and therefore be able to improve the care of the patient's who have had stroke'.

As well as analysis on patients who suffer with heart failure to better personalise their treatment and more recently working on Covid-19 patients, 'to detect lung disease related to Covid-19 infections'.

Quick facts: Sensyne Health PLC

Price: 157.5 GBX

Market: AIM
Market Cap: £250.56 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sensyne Health PLC named herein, including the promotion by the Company of Sensyne Health PLC in any Content on the Site, the Company receives...



Sensyne Health launch first digital health product in the U.S for diabetes...

Sensyne Health's CEO (LON:SENS) Lord Paul Drayson talks to Proactive London about their first digital health product in the U.S that can remotely monitor for diabetes in pregnancy. The group's partner Cognizant will oversee the roll-out of GDm-Health across the Atlantic. Drayson talks...

on 15/12/20

2 min read